Prerenal Acute Kidney Injury Management

Initial Management

The primary treatment for prerenal acute kidney injury (AKI) is to identify and correct the underlying cause of decreased renal perfusion through volume expansion in hypovolemic patients, discontinuation of nephrotoxic medications, and restoration of adequate blood pressure, as recommended by the American College of Physicians 1
Immediately review all medications and withdraw potential nephrotoxic agents including diuretics, NSAIDs, ACE inhibitors, ARBs, and vasodilators, according to the European Society of Cardiology 2, 1
Perform plasma volume expansion in patients with clinically suspected hypovolemia using isotonic crystalloids as first-line fluid therapy, as suggested by the American College of Surgeons 1
Target a mean arterial pressure of at least 65 mmHg to ensure adequate renal perfusion, as recommended by the Society of Critical Care Medicine 1
For patients with cirrhosis and ascites with prerenal AKI, administer intravenous albumin at 1 g/kg bodyweight (maximum 100 g) for two consecutive days, as recommended by the European Association for the Study of the Liver 3, 2

Use isotonic crystalloids rather than colloids as initial management for volume expansion in most cases of prerenal AKI, according to the American College of Physicians 1
For patients with acute gastrointestinal bleeding, administer packed red blood cells to maintain hemoglobin levels between 7-9 g/dL, as recommended by the European Society of Gastrointestinal Endoscopy 3, 4
In patients with tense ascites, perform therapeutic paracentesis with albumin infusion to improve renal function, as suggested by the American Association for the Study of Liver Diseases 3, 4
Monitor for signs of fluid overload using urine output, vital signs, and when indicated, echocardiography, as recommended by the Heart Failure Society of America 1
Avoid hydroxyethyl starches due to increased risk of worsening AKI, according to the European Society of Anesthesiology 1

Discontinue the "triple whammy" combination of NSAIDs, diuretics, and ACE inhibitors/ARBs, which significantly increases AKI risk, as recommended by the American College of Cardiology 5, 1
Do not use diuretics to treat prerenal AKI except for managing volume overload after adequate renal perfusion has been restored, according to the National Kidney Foundation 1
Be cautious with nephrotoxic antibiotics (aminoglycosides, vancomycin), contrast agents, and other potentially nephrotoxic drugs, as suggested by the Infectious Diseases Society of America 6, 7
Remember that each additional nephrotoxin increases the odds of developing AKI by 53%, with risk compounding when multiple nephrotoxins are used, according to the National Institute of Diabetes and Digestive and Kidney Diseases 5, 1

For patients with cirrhosis and prerenal AKI, discontinue beta-blockers in addition to diuretics, as recommended by the European Association for the Study of the Liver 3
In hepatorenal syndrome AKI (HRS-AKI), after ruling out other causes and if not responding to volume expansion, administer vasoconstrictors (terlipressin, norepinephrine, or midodrine plus octreotide) along with albumin, as suggested by the American Association for the Study of Liver Diseases 4, 1
For large volume paracentesis (>5 L), administer IV albumin to prevent post-paracentesis circulatory dysfunction and subsequent AKI, according to the European Association for the Study of the Liver 6
In patients with spontaneous bacterial peritonitis, administer albumin infusion according to current guidelines to prevent AKI, as recommended by the Infectious Diseases Society of America 2

Closely monitor renal function and urine output, particularly in the first 48-72 hours, as suggested by the National Kidney Foundation 2, 1
Measure electrolytes every 12-24 hours during acute management, according to the American College of Physicians 1
Reassess the etiology and consider nephrology consultation for patients with persistent AKI (>48 hours), as recommended by the American Society of Nephrology 5, 1
Continue nephrotoxin avoidance during the recovery phase to prevent re-injury, according to the National Institute of Diabetes and Digestive and Kidney Diseases 5, 1

Avoid using furosemide in hemodynamically unstable patients with prerenal AKI, as it can worsen volume depletion and further reduce renal perfusion, as recommended by the American College of Emergency Physicians 1
Do not delay fluid resuscitation in hypovolemic patients with prerenal AKI, according to the American College of Surgeons 1
Avoid combining multiple nephrotoxic medications, especially in high-risk patients, as suggested by the National Kidney Foundation 7, 5
Do not use eGFR equations designed for chronic kidney disease to assess renal function in AKI, as they are inaccurate in this setting, according to the National Institute of Diabetes and Digestive and Kidney Diseases 1

For Stage 1 AKI: Remove risk factors, provide volume expansion if hypovolemic, and closely monitor renal function, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) 2
For Stage 2-3 AKI: Consider vasopressor therapy if fluid resuscitation fails to restore adequate blood pressure, according to the Society of Critical Care Medicine 2, 1
For persistent AKI despite appropriate interventions, consider renal replacement therapy based on the patient's overall clinical condition, as suggested by the American Society of Nephrology 1